Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
Metrics: PDF 1698 views | HTML 1659 views | ?
Rekha Gyanchandani1,2, Karthik J. Kota3,4, Amruth R. Jonnalagadda1, Tanya Minteer1, Beth A. Knapick1, Steffi Oesterreich1,2, Adam M. Brufsky1,4,*, Adrian V. Lee1,2,*, Shannon L. Puhalla1,4,*
1Women’s Cancer Research Center, Magee-Womens Research Institute, Pittsburgh, PA, USA
2Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA
3University of Pittsburgh Medical Center (UPMC) Presbyterian, University of Pittsburgh, Pittsburgh, PA, USA
4Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA, USA
*These authors have senior authorship of this article
Adam M. Brufsky, email: email@example.com
Adrian V. Lee, email: firstname.lastname@example.org
Shannon L. Puhalla, email: email@example.com
Keywords: ESR1 mutations, metastatic breast cancer, circulating cell-free DNA, aromatase inhibitor, cdk4/6 inhibitor
Received: June 01, 2016 Accepted: July 19, 2016 Published: August 19, 2016
ESR1 mutations are frequently acquired in hormone-resistant metastatic breast cancer (MBC). CDK4/6 inhibition along with endocrine therapy is a promising strategy in hormone receptor-positive MBC. However, the incidence and impact of ESR1 mutations on clinical outcome in patients treated with CDK4/6 inhibitors have not been defined. In this study, we evaluated the frequency of ESR1 mutations in cfDNA from 16 patients with MBC undergoing palbociclib and letrozole therapy. Four common ESR1 mutations (D538G, Y537C, Y537N, and Y537S) were analyzed in serial blood draws using ddPCR. Mutation rate was 31.3% (5/16) (n=3; de novo, n=2; acquired). D538G was the most frequent mutation (n=3), followed by Y537N and Y537S (n=2). One patient showed multiple ESR1 mutations. Mutations were enriched during therapy. Progression-free survival (PFS) and overall survival (OS) were similar in patients with and without mutation detected at any given time during treatment. However, PFS was significantly shorter in patients with ESR1 mutation at initial blood draw (3.3 versus 9.0 months, P-value=0.038). In conclusion, ESR1 mutation prevalence is consistent with recent studies in hormone-refractory breast cancer. Further, treatment with palbociclib and letrozole does not prevent selection of ESR1 mutations in later lines of therapy. Larger studies are warranted to validate these findings.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.